TITLE

Thiazolidinediones and cardiovascular outcomes in type 2 diabetes

AUTHOR(S)
Singh, Sonal; Furberg, Curt D.
PUB. DATE
January 2009
SOURCE
Heart;Jan2009, Vol. 95 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on the study of thiazolidinediones and cardiovascular outcomes in type 2 diabetes conducted by the American Diabetes Association and the European Association for the Study of Diabetes Update. The unfavorable findings from the three trials reported in June 2008 have not been fully realised by the medical community. The authors recommend restrictions in the use of thiazolidininediones and questioned the rationale for leaving rosiglitazone on the market.
ACCESSION #
35945973

 

Related Articles

  • Transparency: Where Have All the Experts Gone? Kruger, Davida F. // Diabetes Spectrum;Spring2008, Vol. 21 Issue 2, p69 

    The article focuses on achieving transparency in diabetes care. Accordingly, the author wonders if, in this age of transparency, she is an expert or a conflicted participant unable to provide unbiased opinions to different constituencies. She says that providing cutting-edge, up-to-date...

  • Novel therapies for type 2 diabetes on the horizon. Burant, Charles F. // Endocrine Today;Aug2011, Vol. 9 Issue 8, p18 

    The article offers information on a study presented at the American Diabetes Association Scientific Sessions in San Diego, California on June 24-28, 2011 that explored the potential therapeutic efficacy of several compounds including sodium-glucose co-transporter inhibitors, bile acid...

  • MEDICAL FAMILY THERAPY CASEBOOK. Munshower, John C. // Families, Systems & Health: The Journal of Collaborative Family ;Winter2004, Vol. 22 Issue 4, p497 

    This article deals with the difficulties often encountered by physicians treating patients with diabetes. Group visits are a unique approach to tackling these difficulties. Group visits, specific for diabetes, ensure continuing diabetic education, ensure that appropriate testing is being done,...

  • Report: Aerosolized insulin could replace needles.  // Healthcare Purchasing News;Sep2001, Vol. 25 Issue 9, p14 

    Reports on the findings of research papers at the annual meeting of the American Diabetes Association which held that insulin taken by the mouth through aerosolized puffs quickly passed into mucus membranes of the cheeks and entered the bloodstream. Significance of the finding; Statement from...

  • Studies confer teplizumab benefit in type I diabetes.  // Endocrine Today;Aug2011, Vol. 9 Issue 8, p20 

    The article offers information on a study presented at the American Diabetes Association Scientific Sessions in San Diego, California on June 24-28, 2011 that explored the efficacy of anti-CD3 medication teplizumab in improving beta-cell function and preserving C-peptide levels in patients with...

  • Lifestyle intervention, metformin eased financial burden of diabetes in DPP.  // Endocrine Today;Aug2011, Vol. 9 Issue 8, p22 

    The article offers information on a study presented at the American Diabetes Association Scientific Sessions in San Diego, California on June 24-28, 2011 that explored the cost-effectiveness of the Diabetes Prevention Program.

  • ORGANIZATION SECTION.  // Diabetes;Feb2010, Vol. 59 Issue 2, p550 

    A calendar of diabetes-related events to be held in 2010 is presented, which include the 57th Annual Advanced Postgraduate Course on February 5 to 7 in San Francisco, California, the 70th Scientific Sessions of the American Diabetes Association (ADA) in Orlando, Florida on June 25 to 29 and the...

  • What is the best strategy for impaired glucose tolerance in nonpregnant adults? Rao, Shobha; Kakkar, Sonia; Wilder, Laura; Meza, James; Tarokh, Saeed // Journal of Family Practice;Jun2005, Vol. 54 Issue 6, p543 

    The article presents an evidence-based answer to the clinical question related to strategy for impaired glucose tolerance in nonpregnant adults. The best treatment strategy for impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) is lifestyle intervention with a structured weight...

  • RISE, RIDE: Ranibizumab bested sham injection in diabetic macular edema. Boyer, David S. // Endocrine Today;Aug2011, Vol. 9 Issue 8, p19 

    The article offers information on a study presented at the American Diabetes Association Scientific Sessions in San Diego, California on June 24-28, 2011 that explored the link between treatment with ranibizumab and improvement in corrected visual acuity and retinal thickness.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics